Last reviewed · How we verify
NCT01303705
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Phase 1 trial testing Anti-OX40 in Metastatic Prostate Cancer in 13 participants. Completed in 5 July 2016.
5 July 2016
Quick facts
| Lead sponsor | Providence Health & Services |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 14 October 2010 |
| Primary completion | 5 July 2016 |
| Estimated completion | 5 July 2016 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Anti-OX40 — full drug profile →
- Radiation
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →
- Cancer of the Prostate — all drugs for Cancer of the Prostate →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Providence Health & Services — full company profile →
Who can join
18 and older, male only, with Metastatic Prostate Cancer or Cancer of the Prostate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.
Li C, Jiang P, Wei S, Xu X, et al · · 2020 · cited 679× · PMID 32680511 · DOI 10.1186/s12943-020-01234-1 -
Eradication of spontaneous malignancy by local immunotherapy.
Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, et al · · 2018 · cited 282× · PMID 29386357 · DOI 10.1126/scitranslmed.aan4488 -
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, et al · · 2017 · cited 249× · PMID 28855348 · DOI 10.1158/1078-0432.ccr-16-2677 -
Antibody-based immunotherapy of cancer.
Weiner LM, Murray JC, Shuptrine CW. · · 2012 · cited 204× · PMID 22424219 · DOI 10.1016/j.cell.2012.02.034 -
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.
Bartkowiak T, Curran MA. · · 2015 · cited 196× · PMID 26106583 · DOI 10.3389/fonc.2015.00117 -
Combinations of immunotherapy and radiation in cancer therapy.
Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, et al · · 2014 · cited 189× · PMID 25506582 · DOI 10.3389/fonc.2014.00325 -
Intratumoral immunization: a new paradigm for cancer therapy.
Marabelle A, Kohrt H, Caux C, Levy R. · · 2014 · cited 185× · PMID 24691639 · DOI 10.1158/1078-0432.ccr-13-2116 -
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Linch SN, McNamara MJ, Redmond WL. · · 2015 · cited 174× · PMID 25763356 · DOI 10.3389/fonc.2015.00034
Verify or expand the search:
- PubMed search for NCT01303705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Prostate Cancer
Currently open trials in the same condition.
- NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
- NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
- NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting
Other Providence Health & Services trials
Trials by the same sponsor.
- NCT06175000 — Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti · Phase 2 · recruiting
- NCT04987996 — GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients · Phase 2 · withdrawn
- NCT05349890 — Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) · Phase 1 · active not recruiting
- NCT04796584 — Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication · terminated
- NCT04417699 — SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01303705 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Providence Health & Services
- Last refreshed: 29 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01303705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing